drugset / Trial / NCT04075136
Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
RandomizedParallel-groupSingle-blindTreatment
Summary
Optical Coherent Tomography Angiography (OCTA)-Directed PDT Triple Therapy for Treatment-Naïve Patients with Exudative Age-related Macular Degeneration (ARMD) versus Standard of Care Anti-VEGF Monotherapy
Timeline
- Start
- 2023-03-30
- Primary completion
- 2024-11
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |
| Subject | Triamcinolone Acetonide | Other / unclassified | 2 mg | Intravitreal |
| Subject | Verteporfin | Other / unclassified | 6 mg/m2 | — |